Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 65

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Cancer Cell Resistance Against the Clinically Investigated Thiosemicarbazone COTI-2 Is Based on Formation of Intracellular Copper Complex Glutathione Adducts and ABCC1-Mediated Efflux

Bormio Nunes, Julia H., Hager, Sonja, Mathuber, Marlene, Pósa, Vivien, Roller, Alexander, Enyedy, Éva A., Stefanelli, Alessia, Berger, Walter, Keppler, Bernhard K., Heffeter, Petra, Kowol, Christian R. · 2020 · Journal of Medicinal Chemistry

Abstract

COTI-2 is a novel anticancer thiosemicarbazone in phase I clinical trial. However, the effects of metal complexation (a main characteristic of thiosemicarbazones) and acquired resistance mechanisms are widely unknown. Therefore, in this study, the copper and iron complexes of COTI-2 were synthesized and evaluated for their anticancer activity and impact on drug resistance in comparison to metal-free thiosemicarbazones. Investigations using Triapine-resistant SW480/Tria and newly established COTI-2-resistant SW480/Coti cells revealed distinct structure–activity relationships. SW480/Coti cells were found to overexpress ABCC1, and COTI-2 being a substrate for this efflux pump. This was unexpected, as ABCC1 has strong selectivity for glutathione adducts. The recognition by ABCC1 could be explained by the reduction kinetics of a ternary Cu-COTI-2 complex with glutathione. Thus, only thiosemicarbazones forming stable, nonreducible copper(II)-glutathione adducts are recognized and, in turn, effluxed by ABCC1. This reveals a crucial connection between copper complex chemistry, glutathione interaction, and the resistance profile of clinically relevant thiosemicarbazones.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.0c01277

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 42

  1. Lobana, 2009, Bonding and structure trends of thiosemicarbazone derivatives of metals-An overview, Coord. Chem. Rev., 253, 977, 10.1016/j.ccr.2008.07.004 · doi:10.1016/j.ccr.2008.07.004
  2. Beraldo, 2004, The wide pharmacological versatility of semicarbazones, thiosemicarba-zones and their metal complexes, Mini-Rev. Med. Chem., 4, 31, 10.2174/1389557043487484 · DOI · Paper page
  3. Yu, 2009, Thiosemicarbazones from the old to new: Iron chelators that are more than just ribonucleotide reductase inhibitors, J. Med. Chem., 52, 5271, 10.1021/jm900552r · DOI · Paper page
  4. Heffeter, 2019, Anticancer thiosemicarbazones: chemical properties, interaction with iron metabolism, and resistance development, Antioxid. Redox Signaling, 30, 1062, 10.1089/ars.2017.7487 · DOI · Paper page
  5. Lovejoy, 2011, Antitumor Activity of Metal-Chelating Compound Dp44mT Is Mediated by Formation of a Redox-Active Copper Complex That Accumulates in Lysosomes, Cancer Res., 71, 5871, 10.1158/0008-5472.CAN-11-1218 · DOI · Paper page
  6. Hager, 2020, High copper complex stability and slow reduction kinetics as key parameters for improved activity, paraptosis induction and impact on drug-resistant cells of anticancer thiosemicarbazones, Antioxid. Redox Signaling, 33, 395, 10.1089/ars.2019.7854 · doi:10.1089/ars.2019.7854
  7. Miah, 2010, Triapine in clinical practice, Eur. J. Clin. Med. Oncol., 2, 1
  8. Kowol, 2009, Impact of Metal Coordination on Cytotoxicity of 3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone (Triapine) and Novel Insights into Terminal Dimethylation, J. Med. Chem., 52, 5032, 10.1021/jm900528d · DOI · Paper page
  9. Kowol, 2016, Impact of Stepwise NH2-Methylation of Triapine on the Physicochemical Properties, Anticancer Activity, and Resistance Circumvention, J. Med. Chem., 59, 6739, 10.1021/acs.jmedchem.6b00342 · DOI
  10. Hager, 2018, The thiosemicarbazone Me2NNMe2 induces paraptosis by disrupting the ER thiol redox homeostasis based on protein disulfide isomerase inhibition, Cell Death Dis., 9, 1052, 10.1038/s41419-018-1102-z · doi:10.1038/s41419-018-1102-z
  11. Guo, 2016, The novel thiosemicarbazone, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), inhibits neuroblastoma growth in vitro and in vivo via multiple mechanisms, J. Hematol. Oncol., 9, 98, 10.1186/s13045-016-0330-x · DOI
  12. Seebacher, 2016, A mechanism for overcoming P-glycoprotein-mediated drug resistance: novel combination therapy that releases stored doxorubicin from lysosomes via lysosomal permeabilization using Dp44mT or DpC, Cell Death Dis., 7, e2510, 10.1038/cddis.2016.381 · DOI
  13. Salim, 2016, COTI-2, a new anticancer drug currently under clinical investigation, targets mutant p53 and negatively modulates the PI3K/AKT/mTOR pathway, Eur. J. Cancer, 69, S19, 10.1016/S0959-8049(16)32638-7 · DOI
  14. Lindemann, 2019, COTI-2, a novel thiosemicarbazone derivative, exhibits antitumor activity in HNSCC through p53-dependent and -independent mechanisms, Clin. Cancer Res., 25, 5650, 10.1158/1078-0432.CCR-19-0096 · DOI · Paper page
  15. Salim, 2016, COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo, Oncotarget, 7, 41363, 10.18632/oncotarget.9133 · DOI · Paper page
  16. Miklos, 2015, Triapine-mediated ABCB1 induction via PKC induces widespread therapy unresponsiveness but is not underlying acquired triapine resistance, Cancer Lett., 361, 112, 10.1016/j.canlet.2015.02.049 · DOI
  17. Heffeter, 2012, Impact of terminal dimethylation on the resistance profile of α-N-heterocyclic thiosemicarbazones, Biochem. Pharmacol., 83, 1623, 10.1016/j.bcp.2012.03.004 · DOI
  18. Wiese, 2019, The A-B-C of small-molecule ABC transport protein modulators: From inhibition to activation─a case study of multidrug resistance-associated protein 1 (ABCC1), Med. Res. Rev., 39, 2031, 10.1002/med.21573 · DOI
  19. Cole, 2006, Transport of glutathione and glutathione conjugates by MRP1, Trends Pharmacol. Sci., 27, 438, 10.1016/j.tips.2006.06.008 · DOI · Paper page
  20. Lemke, 1977, Synthesis of 5,6-dihydro-8(7H)-quinolinone thiosemicarbazones as potential antitumor agents, J. Med. Chem., 20, 1351, 10.1021/jm00220a026 · doi:10.1021/jm00220a026
  21. Kowol, 2007, Effect of metal ion complexation and chalcogen donor identity on the antiproliferative activity of 2-acetylpyridine N,N-dimethyl(chalcogen)semicarbazones, J. Inorg. Biochem., 101, 1946, 10.1016/j.jinorgbio.2007.07.026 · doi:10.1016/j.jinorgbio.2007.07.026
  22. Pessôa, 2001, 2-Formylpyridinethiosemicarbazone and methyl derivatives: Spectroscopic studies, Polyhedron, 20, 3133, 10.1016/S0277-5387(01)00928-7 · doi:10.1016/s0277-5387(01)00928-7
  23. ChemAxon., 2012, Instant J Chem/MarvinSketch
  24. Richardson, 2006, Dipyridyl Thiosemicarbazone Chelators with Potent and Selective Antitumor Activity Form Iron Complexes with Redox Activity, J. Med. Chem., 49, 6510, 10.1021/jm0606342 · DOI · Paper page
  25. Kowol, 2007, Gallium(III) and Iron(III) Complexes of α-N-Heterocyclic Thiosemicarbazones: Synthesis, Characterization, Cytotoxicity, and Interaction with Ribonucleotide Reductase, J. Med. Chem., 50, 1254, 10.1021/jm0612618 · doi:10.1021/jm0612618
  26. Kowol, 2012, Mechanisms underlying reductant-induced reactive oxygen species formation by anticancer copper(II) compounds, J. Biol. Inorg. Chem., 17, 409, 10.1007/s00775-011-0864-x · DOI
  27. Korp, 1978, Crystal and molecular structure of (Z)-5,6-dihydro-8(7H)quinolinone thiosemicarbazone, J. Cryst. Mol. Struct., 8, 115, 10.1007/BF01370422 · doi:10.1007/bf01370422
  28. Joseph, 2006, Structural, antimicrobial and spectral studies of copper(II) complexes of 2-benzoylpyridine N(4)-phenyl thiosemicarbazone, Polyhedron, 25, 61, 10.1016/j.poly.2005.07.006 · DOI
  29. Beshir, 2008, Synthesis and structure-activity relationships of metal-ligand complexes that potently inhibit cell migration, Bioorg. Med. Chem. Lett., 18, 498, 10.1016/j.bmcl.2007.11.099 · doi:10.1016/j.bmcl.2007.11.099
  30. Saswati, 2015, Synthesis, X-ray structure and in vitro cytotoxicity studies of Cu(I/II) complexes of thiosemicarbazone: special emphasis on their interactions with DNA, Dalton Trans., 44, 6140, 10.1039/C4DT03764B · DOI
  31. Miklos, 2016, Loss of phosphodiesterase 4D mediates acquired triapine resistance via Epac-Rap1-Integrin signaling, Oncotarget, 7, 84556, 10.18632/oncotarget.11821 · DOI
  32. Maleki Vareki, 2018, Novel anti-cancer drug COTI-2 synergizes with therapeutic agents and does not induce resistance or exhibit cross-resistance in human cancer cell lines, PLoS One, 13, 1, 10.1371/journal.pone.0191766 · DOI
  33. Yuan, 2004, Novel di-2-pyridyl–derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment, Blood, 104, 1450, 10.1182/blood-2004-03-0868 · DOI · Paper page
  34. Trondl, 2014, Triapine and a More Potent Dimethyl Derivative Induce Endoplasmatic Reticulum Stress in Cancer Cells, Mol. Pharmaceutics, 85, 451, 10.1124/mol.113.090605 · DOI
  35. Cserepes, 2020, Unshielding Multidrug Resistant Cancer through Selective Iron Depletion of P-Glycoprotein–Expressing Cells, Cancer Res., 80, 663, 10.1158/0008-5472.CAN-19-1407 · DOI
  36. Jansson, 2010, Novel Thiosemicarbazones of the ApT and DpT Series and Their Copper Complexes: Identification of Pronounced Redox Activity and Characterization of Their Antitumor Activity, J. Med. Chem., 53, 5759, 10.1021/jm100561b · DOI · Paper page
  37. Park, 2016, Copper and conquer: copper complexes of di-2-pyridylketone thiosemicarbazones as novel anti-cancer therapeutics, Metallomics, 8, 874, 10.1039/C6MT00105J · DOI
  38. Ishiguro, 2014, Distinct mechanisms of cell-kill by triapine and its terminally dimethylated derivative Dp44mT due to a loss or gain of activity of their copper(II) complexes, Biochem. Pharmacol., 91, 312, 10.1016/j.bcp.2014.08.006 · DOI
  39. Drew, 1984, The effects of buthionine sulphoximine (BSO) on glutathione depletion and xenobiotic biotransformation, Biochem. Pharmacol., 33, 2989, 10.1016/0006-2952(84)90598-7 · DOI
  40. Santoro, 2020, The Glutathione/Metallothionein System Challenges the Design of Efficient O2-Activating Copper Complexes, Am. Ethnol., 132, 7904, 10.1002/ange.201916316 · DOI
  41. Santoro, 2019, Reactivity of Cu (ii)–, Zn (ii)–and Fe (ii)–thiosemicarbazone complexes with glutathione and metallothionein: from stability to dissociation to transmetallation, Metallomics, 11, 994, 10.1039/C9MT00061E · DOI
  42. Kalinowski, 2016, Redox cycling metals: Pedaling their roles in metabolism and their use in the development of novel therapeutics, Biochim. Biophys. Acta, Mol. Cell Res., 1863, 727, 10.1016/j.bbamcr.2016.01.026 · DOI

Cited by

See all 65

Metadata

Authors
Bormio Nunes, J. H., Hager, S., Mathuber, M., Pósa, V., Roller, A., Enyedy, E. A., Stefanelli, A., Berger, W., Keppler, B. K., Heffeter, P., & Kowol, C. R.
Venue
Journal of Medicinal Chemistry
Published
2020-11-16
Volume
63
Issue
22
Pages
13719-13732
ISSN
  • 0022-2623
  • 1520-4804
Cited by
65
References
1
Language
en
Funders
  • Österreichischen Akademie der Wissenschaften (NA)
  • Austrian Science Fund (P31923)
  • OeAD-GmbH (NA)
  • Nemzeti Kutatási Fejlesztési és Innovációs Hivatal (FK 124240, TUDFO/47138-1/2019-ITM)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cancer Cell Resistance Against the Clinically Investigated Thiosemicarbazone COTI-2 Is Based on Formation of Intracellular Copper Complex Glutathione Adducts and ABCC1-Mediated Efflux. https://app.cochat.ai/papers/10.1021/acs.jmedchem.0c01277
The paper
Bormio Nunes, J. H., Hager, S., Mathuber, M., Pósa, V., Roller, A., Enyedy, E. A., Stefanelli, A., Berger, W., Keppler, B. K., Heffeter, P., & Kowol, C. R. (2020). Cancer Cell Resistance Against the Clinically Investigated Thiosemicarbazone COTI-2 Is Based on Formation of Intracellular Copper Complex Glutathione Adducts and ABCC1-Mediated Efflux. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.0c01277

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.